Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva
Author:
Affiliation:
1. Division of Endocrinology, Diabetes, and Metabolism, Department of MedicineUniversity of California San Francisco CA USA
2. Institute for Human GeneticsUniversity of California San Francisco CA USA
Funder
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.13823
Reference63 articles.
1. The Natural History of Flare-Ups in Fibrodysplasia Ossificans Progressiva (FOP): A Comprehensive Global Assessment
2. Prevalence of fibrodysplasia ossificans progressiva (FOP) in France: an estimate based on a record linkage of two national databases
3. Age‐ and joint‐specific risk of initial heterotopic ossification in patients who have fibrodysplasia ossificans progressiva;Rocke DM;Clin Orthop Relat Res,1994
4. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva
5. ACVR1 R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A
Cited by 53 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Nitrogen-containing heterocyclic drug products approved by the FDA in 2023: Synthesis and biological activity;European Journal of Medicinal Chemistry;2024-12
2. Fibrodysplasia ossificans progressiva (clinical observation with a brief review of the literature);N.N. Priorov Journal of Traumatology and Orthopedics;2024-07-04
3. Role of the NF-kB signalling pathway in heterotopic ossification: biological and therapeutic significance;Cell Communication and Signaling;2024-03-04
4. Creation of Induced Pluripotent Stem Cells RCMGi014-A Using Reprogramming of Urine Cells of a Patient with Fibrodysplasia Ossificans Progressiva Associated with Heterozygous Mutation in the ACVR1 Gene;Russian Journal of Developmental Biology;2024-02
5. How Activin A Became a Therapeutic Target in Fibrodysplasia Ossificans Progressiva;Biomolecules;2024-01-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3